TOP > 外国特許検索 > ANTIPRURITIC AGENT

ANTIPRURITIC AGENT

外国特許コード F110006064
整理番号 S2010-0110
掲載日 2011年12月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2010JP068695
国際公開番号 WO 2011049200
国際出願日 平成22年10月22日(2010.10.22)
国際公開日 平成23年4月28日(2011.4.28)
優先権データ
  • 特願2009-244528 (2009.10.23) JP
発明の名称 (英語) ANTIPRURITIC AGENT
発明の概要(英語) Provided is a faster-acting antipruritic agent which has little side effects and is efficacious in treating strongly itchy skin diseases such as atopic dermatitis, characterized by comprising, as the active ingredient, a cholecystokinin 2 acceptor agonist such as a peptide having an amino acid sequence that is homologous with a partial amino acid sequence consisting of 7 or more amino acids from the C-terminal side of a peptide having the amino acid sequence represented by SEQ ID NO:1. Val-Ser-Gln-Arg-Thr-Asp-Gly-Glu-Ser-Arg-Ala-His-Leu-Gly-Ala-Leu-Leu-Ala-Arg-Tyr-Ile-Gln-Gln-Ala-Arg-Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys-Asn-Leu-Gln-Asn-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 [SEQ ID NO:1]
従来技術、競合技術の概要(英語) BACKGROUND ART
Atopic dermatitis, contact dermatitis, hives, itching the disorder of the skin such as prurigo (itching: skin scratching the unpleasant sensation of the skin as desired) are often accompanied by. Is itching, scratching it induces to increase due to the behaviors of the exacerbation of the lesions and itching as well as cause a vicious circle, the operation in the daily life and working efficiency is lowered, which results in reduced sleep also inhibit QOL. Therefore, the suppression of itching, skin with a suppression of the inflammatory response in skin is important in the treatment of a disease.
Treatment of skin diseases, various types of synthetic steroid agent has been widely used, with a marked therapeutic effect has been mentioned. However, for use in the steroid is, the effect of preventing the itching does not have to directly, indirectly by suppressing the inflammatory response is effective to suppress the irritation considered. Such as in atopic dermatitis is pruritus, allergic reaction type I derived from mast cells by the phenomenon that is caused by histamine had the thought, for suppression of pruritus, antihistamines and anti-allergy medication is administered as Pnnciples or for use in many cases.
In recent years, including tacrolimus immunosuppressive agent is to be used also for use in (for example, see non-patent document 1). Also tacrolimus, steroids for use in the same manner, the primary mechanism of action inflammation and suppress the reaction but, atopic dermatitis skin disease from the experiments using the mouse disease models, inhibition of scratching behavior by tacrolimus have been observed (for example, see non-patent document 2).
In addition, conventional treatment cannot control severe atopic dermatitis patient, recent exclusively as a steroid for use in the difficulty of using pharmaceuticals for, oral cyclosporine immunosuppressive agent has been studied (for example, see non-patent document 3) and, in regard to, under certain conditions, the use of severe atopic dermatitis is authorized to the patient.
Another approach, itching and skin inflammation reaction or a chemical method for modulating the genetic level has been studied. For example, in patent document 1, which is a kind of neuropeptide cholecystokinin or its analogs containing a, containing a protein of a particular cell regeneration, growth or differentiation-regulating agents and it can be administered, obesity, diabetes, immune system disorders, liver disease, a digestive system disease such as cosmetic surgery at the time of tissue damage or cell regeneration, proliferation or differentiation are methods for treating diseases involving the disclosed, as a specific example, immune system disorders such as atopic dermatitis or as therapeutic agents for the prevention and/of disclosed the use of cholecystokinin.
In addition, Patent Document 2 is, as the active ingredient at least one pharmaceutical agent 1, at least one 1 in order to increase the uptake of a pharmaceutical agent in vivo or in a mixture of a liquid and nanostructures, a pharmaceutical composition comprising a liquid and the disclosed invention, as one embodiment of the invention, using the agent for the treatment of itching neuropeptide disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN
  • 発明者(英語)
  • TOKURA, Yoshiki
  • FUKAMACHI, Akiko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close